Seattle Genetics Gets $136M Total

Xconomy Seattle — 

Seattle Genetics, the Bothell, WA-based developer of antibody drugs for cancer, said today that underwriters of its stock offering have exercised their options to buy more shares, which makes the deal worth a total of $136 million. JP Morgan and Goldman Sachs led the offering, which also included Needham & Co., Oppenheimer & Co., RBC Capital Markets, and William Blair & Co. The company, as we described in a feature story earlier this week, has attracted interest partly because it is six months ahead of schedule in the pivotal study of its experimental drug for Hodgkin’s disease.